Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. grew its position in Voyager Therapeutics, Inc. ( NASDAQ:VYGR – Free Report ) by 0.

9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,215,441 shares of the company’s stock after buying an additional 29,014 shares during the quarter. Vanguard Group Inc.



owned approximately 0.06% of Voyager Therapeutics worth $18,232,000 at the end of the most recent quarter. Several other institutional investors have also made changes to their positions in VYGR.

Picton Mahoney Asset Management lifted its holdings in shares of Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after purchasing an additional 2,444 shares in the last quarter.

Virtu Financial LLC purchased a new position in shares of Voyager Therapeutics during the fourth quarter valued at $100,000. SG Americas Securities LLC raised its position in Voyager Therapeutics by 86.7% during the fourth quarter.

SG Americas Securities LLC now owns 23,044 shares of the company’s stock valued at $131,000 after buying an additional 10,704 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in Voyager Therapeutics by 23.9% in the 4th quarter.

Allspring Global Investments Holdings LLC now owns 39,313 shares of the company’s stock worth $223,000 after acquiring an additional 7,573 shares in the last quarter. Finally, Empowered Funds LLC boosted its position in Voyager Therapeutics by 5.3% during the 4th quarter.

Empowered Funds LLC now owns 47,206 shares of the company’s stock worth $268,000 after acquiring an additional 2,397 shares during the period. 48.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In A number of research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, April 8th.

Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Canaccord Genuity Group lowered their target price on Voyager Therapeutics from $14.00 to $12.

00 and set a “buy” rating on the stock in a research note on Thursday, March 13th. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the stock an “overweight” rating in a research note on Wednesday, March 12th.

Finally, Wedbush reissued an “outperform” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.

com, the company has an average rating of “Buy” and an average price target of $13.97. Voyager Therapeutics Trading Down 2.

5 % VYGR stock opened at $3.13 on Thursday. The firm has a market cap of $172.

80 million, a P/E ratio of 4.41 and a beta of 1.02.

Voyager Therapeutics, Inc. has a 1-year low of $2.75 and a 1-year high of $9.

55. The business’s 50 day moving average is $3.80 and its 200-day moving average is $5.

34. Voyager Therapeutics ( NASDAQ:VYGR – Get Free Report ) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.

59) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24).

Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%.

The firm had revenue of $4.39 million during the quarter, compared to analyst estimates of $16.58 million.

During the same quarter last year, the firm earned $1.25 earnings per share. Sell-side analysts forecast that Voyager Therapeutics, Inc.

will post -0.91 EPS for the current year. Insiders Place Their Bets In other news, CEO Alfred Sandrock sold 10,885 shares of the stock in a transaction that occurred on Wednesday, April 2nd.

The shares were sold at an average price of $3.43, for a total transaction of $37,335.55.

Following the sale, the chief executive officer now directly owns 430,931 shares of the company’s stock, valued at $1,478,093.33. This represents a 2.

46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link . Insiders own 4.

53% of the company’s stock. Voyager Therapeutics Profile ( Free Report ) Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease.

Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. Read More Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics, Inc.

( NASDAQ:VYGR – Free Report ). Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .

.